原发性肝细胞肝癌患者血清DNMT1、M2BPGi水平及与预后的关系OA
Relationship between the levels of serum DNMT1 and M2BPGi and prognosis in patients with primary liver cancer
目的:探究原发性肝细胞肝癌(HCC)患者血清 DNA 甲基化酶1(DNMT1)、Mac-2 结合蛋白糖基化异构体(M2BPGi)水平及其与预后的关系.方法:选取2017 年5 月至2021 年7 月中国人民解放军联勤保障部队第910 医院收治 HCC 患者100 例、体检健康者100 例分别作为观察组、对照组.比较两组受试者血清 DNMT1、M2BPGi 水平,多元回归分析血清 DNMT1、M2BPGi 水平与临床病理特征的关系,随访 3 年,比较不同受试者血清 DNMT1、M2BPGi 水平患者预后生存率.结果:观察组受试者血清DNMT1、M2BPGi 水平均高于对照组(P<0.05);甲胎蛋白≥400 U/ml、乙肝表面抗原阳性、临床分期Ⅲ～Ⅳ期、中低分化及有淋巴结转移患者血清 DNMT1、M2BPGi 水平分别高于甲胎蛋白<400 U/ml、乙肝表面抗原阴性、临床分期Ⅰ～Ⅱ期、高分化及无淋巴结转移患者(P<0.05);临床分期(偏回归系数=0.720/0.715)、甲胎蛋白(偏回归系数=0.717/0.741)、分化程度(偏回归系数=0.764/0.819)、乙肝表面抗原(偏回归系数=0.802/0.795)及淋巴结转移(偏回归系数=0.804/0.802)均为 HCC 患者 DNMT1、M2BPGi 的影响因素(P<0.05);DNMT1 高水平受试者亚组3 年总生存率为40.82%,明显低于低水平亚组63.83%(P<0.05);M2BPGi 高水平受试者亚组3 年总生存率为43.14%,明显低于低水平亚组 62.22%(P<0.05);DNMT1 高水平亚组+M2BPGi 高水平亚组、DNMT1 低水平亚组+M2BPGi 高水平亚组、DNMT1 高水平亚组+M2BPGi 低水平亚组、DNMT1 低水平亚组+M2BPGi低水平受试者亚组3 年生存率分别为40.82%、66.67%、74.47%、91.11%,4 组比较差异有统计学意义(P<0.05).结论:血清 DNMT1、M2BPGi 在 HCC 患者水平较高,且与患者病理特征有关,检测血清 DNMT1、M2BPGi 有助于预测患者预后生存.
Objective:To investigate the levels of serum DNA methylase 1(DNMT1),Mac-2 binding protein glycosylated isoform(M2BPGi)and their relationship with prognosis in patients with primary hepatocellular carcinoma(HCC).Methods:One hundred cases of HCC patients admitted to The 910th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force and One hundred cases of healthy people with physical examination from May 2017 to July 2021 were selected as observation group and control group,respectively.The levels of DNMT1 and M2BPGi in the serum of the two groups were compared.The relationship between serum DNMT1 and M2BPGi levels and clinical pathological characteristics was analyzed using multiple regression analysis.After a 3-year follow-up,the survival rate of patients with different levels of serum DNMT1 and M2BPGi was compared.Results:The levels of serum DNMT1 and M2BPGi in the observation group were higher than those in the control group(P<0.05).Patients with AFP≥400 U/ml,HBsAg positive,clinical stage Ⅲ-Ⅳ,moderately and poorly differentiated,and lymph node metastasis had higher serum DNMT1 and M2BPGi levels than patients with AFP<400 U/ml,HBsAg negative,clinical stage Ⅰ-Ⅱ,well differentiated,and no lymph node metastasis(P<0.05).Clinical stage(biased regression coefficient=0.720/0.715),alpha-fetoprotein(biased regression coefficient=0.717/0.741),degree of differentiation(biased regression coefficient=0.764/0.819),hepatitis B surface antigen(biased regression coefficient=0.802/0.795),and lymph node metastasis(biased regression coefficient=0.804/0.802)were all the HCC patients with DNMT1 and M2BPGi(P<0.05).The 3-year overall survival rate of the high-level DNMT1 subgroup was40.82%,which was significantly lower than that of the low-level subgroup(63.83%)(P<0.05).The 3-year overall survival rate of the high-level subgroup of M2BPGi was 43.14%,which was significantly lower than that of the low-level subgroup's 62.22%(P<0.05).The 3-year survival rates of the DNMT1 high-level subgroup+M2BPGi high-level subgroup,DNMT1 low-level subgroup+M2BPGi high-level subgroup,DNMT1 high-level subgroup+M2BPGi low-level subgroup,and DNMT1 low-level subgroup+M2BPGi low-level subgroup were 40.82%,66.67%,74.47%,and 91.11%,respectively.The differences among the four groups were statistically significant(P<0.05).Conclusion:Serum DNMT1 and M2BPGi levels are high in HCC patients and correlate with patients'pathologic features,and detection of serum DNMT1 and M2BPGi can help to predict patients' prognostic survival.
许伟雄;杜丕波;蓝亮光;方超兰;叶永坚
中国人民解放军联勤保障部队第910医院检验科(福建 泉州,362000)中国人民解放军联勤保障部队第910医院检验科(福建 泉州,362000)杭州市富阳区医院检验科中国人民解放军联勤保障部队第910医院检验科(福建 泉州,362000)中国人民解放军联勤保障部队第910医院检验科(福建 泉州,362000)
医药卫生
原发性肝细胞肝癌DNA甲基化酶1Mac-2结合蛋白糖基化异构体病理特征预后
primary hepatocellular carcinomaDNA methyltransferase1Mac-2 binding protein glycosylation isoformpathological characteristicsprognosis
《中西医结合肝病杂志》 2026 (5)
574-578,5
评论